Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMvigor210
  • Sponsors Roche
  • Most Recent Events

    • 12 Aug 2019 Planned End Date changed from 18 May 2019 to 28 Mar 2020.
    • 04 Jun 2019 Results of post-hoc analysis of this and other two trials (NCT01375842 & NCT02951767) assessing efficacy of atezolizumab in advanced/metastatic urothelial carcinoma patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top